infohep news

• Treatment for people who use drugs

  Conditional cash transfers may improve HCV screening and treatment in drug users

  Keith Alcorn / 22 January 2019

  Conditional cash transfers – giving money to encourage use of services – may be needed to reach drug users for hepatitis C testing and treatment if they are either unaware of hepatitis ...

• Treatment for people who use drugs

  Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veins

  Keith Alcorn / 16 January 2019

  Despite access to hepatitis C treatment, many people who inject drugs still perceive numerous barriers to starting treatment, including the attitudes of healthcare workers, the difficulty of juggling treatment with competing demands, a ...

• International policy

  Lancet commission sets agenda for the elimination of viral hepatitis

  Keith Alcorn / 10 January 2019

  Viral hepatitis leads to around 1.3 million deaths a year, approximately 257 million people are living with hepatitis B virus (HBV) and 71 million with hepatitis C virus (HCV). Viral hepatitis ...

• Antiviral therapy

  Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year

  Liz Highleyman / 08 January 2019

  Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ...

• Treatment for people living with HIV and HCV

  Co-infection with HIV and HCV does not increase the risk of end-stage liver disease or liver cancer

  Keith Alcorn / 04 January 2019

  People with HIV and hepatitis C are no longer at higher risk of end-stage liver disease than people with hepatitis C alone, and the trend is probably associated with the improved effectiveness ...